Multimodal AI-Driven Out-of-Hospital Management for Hypertension and Cardiometabolic Risk
NCT07917676, Not applicable, Not yet recruiting, China National Center for Cardiovascular Diseases
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Multimodal AI-Driven Out-of-Hospital Management for Hypertension and Cardiometabolic Risk | ClinicalTrials.gov |
| NCT number | NCT07917676 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 150 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | China National Center for Cardiovascular Diseases | ClinicalTrials.gov |
| Conditions | Hypertension, Hyperglycemia, Dyslipidemia | ClinicalTrials.gov |
| Interventions | Hybrid AI-Enabled Out-of-Hospital Health Management, Standard Out-of-Hospital Guidance | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-04 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Proportion of Participants Achieving Blood Pressure Control and Control of at Least One Glycemic or Lipid Indicator | At 6 months after randomization | Proportion of participants achieving both: (1) blood pressure \<140/90 mmHg for general hypertension, or \<130/80 mmHg for participants with metabolic syndrome; and (2) at least one glycemic or lipid target. Glycemic target: fasting plasma glucose \<7.0 mmol/L and HbA1c \<7.0%. LDL-C target: \<2.6 mmol/L for intermediate ASCVD risk or \<1.8 mmol/L for high/very high ASCVD risk. | ClinicalTrials.gov |
| Primary | Composite Treatment and Health-Management Adherence | At 6 months after randomization | Composite adherence assessed using MMAS-8 (score ≥6 indicates good medication adherence) and system data. Good monitoring adherence: ≥4 valid blood pressure measurements/week. Good home-monitoring adherence: ≥80% of AI-recommended tasks completed/week. Dietary/physical-activity adherence is defined in the protocol using achievement of at least 4 of 5 domains (medication, monitoring, diet, physical activity, follow-up), with \>80% of participants meeting this threshold. | ClinicalTrials.gov |
| Secondary | Incidence of Major Adverse Cardiovascular Events (MACE) | From randomization through 6 months | Composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. | ClinicalTrials.gov |
| Secondary | Health-Related Quality of Life (SF-36 Score) | Baseline and 6 months after randomization | Assessed using the 36-Item Short Form Health Survey (SF-36). | ClinicalTrials.gov |
| Secondary | System Satisfaction and Usability (System Usability Scale Score) | At 6 months after randomization | Patient and healthcare-professional satisfaction and usability assessed using the System Usability Scale (SUS). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)